Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women
Abstract
Endometriosis afflicts millions of women worldwide, resulting in the loss of academic, athletic, social, and professional success. Women can experience chronic pain, fertility challenges, and higher risk of cardiovascular disease. As no cure exists, patients require disease management across the lifespan. However, current therapies are suboptimal, and pain is often left untreated. Medications with favorable long-term safety, efficacy, and tolerability are desperately needed. As endometriosis is dependent on angiogenesis for its growth and maintenance, we believe that angiogenesis inhibitors are a promising option for treatment. However, these medications have not yet been studied since the currently approved angiogenesis inhibitors induce severe side effects and are teratogenic, making them inappropriate for use in reproductive-age women. We will overcome this obstacle by repurposing an existing drug (cabergoline) that has an acceptable safety profile as an angiogenesis inhibitor to treat chronic pelvic pain associated with endometriosis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1155411
Entities
People
- Amy Divasta
- Christine B Sieberg
- Marc Laufer
- Mark Hornstein
Organizations
- Boston Children's Hospital